“We are just at the beginning of the revolution in personalized healthcare brought on by advances in microbiome sequencing and other technologies. uBiome has gathered an exciting and extensive group of collaborators to move rapidly to advance this science into clinical interventions.” -Dr. Fasano MD
SAN FRANCISCO (PRWEB) October 03, 2018
uBiome, the leader in microbial genomics, announces the addition of Dr. Alessio Fasano, MD, Division Chief of Pediatric Gastroenterology and Nutrition, W. Allen Walker Chair in Pediatric Gastroenterology and Nutrition, and Director of Mucosal Immunology and Biology Research Center at Massachusetts General Hospital, to its Medical Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Alessio Fasano will bring to uBiome expertise in investigating the composition of and changes in the gastrointestinal microbiota. This appointment will help uBiome continue its advancement in human microbiome research.
“Dr. Alessio Fasano’s comprehensive research on intestinal permeability and the microbiota, as they relate to celiac disease, has broad implications for the future of gut health,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are proud to welcome him to our Medical Advisory Board.”
In 1993, Dr. Fasano founded the University of Maryland School of Medicine Division of Pediatric Gastroenterology and Nutrition. Three years later, he founded the Center for Celiac Research, which specializes in the treatment of patients of all ages with gluten-related disorders. His research lead him to publish a groundbreaking study in 2003 to determine the rate of celiac disease at one in 133 Americans. In 2013, he was appointed Division Chief of Pediatric Gastroenterology and Nutrition and acts as Associate Chief for Basic, Clinical and Translational Research at MassGeneral Hospital for Children. Dr. Fasano is a professor of pediatrics at Harvard Medical School and author of “Gluten Freedom."
About joining uBiome's Medical Advisory Board, Dr. Fasano said, “We are just at the beginning of the revolution in personalized healthcare brought on by advances in microbiome sequencing and other technologies. uBiome has gathered an exciting and extensive group of collaborators to move rapidly to advance this science into clinical interventions.”
In addition to Dr. Alessio Fasano, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutics.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.